Add map linking file name and link so that users can click the cited article and be taken to a link, when publicly available.

knowledge_base.py

@@ -208,6 +208,98 @@ def source_title(filename):
         return f"Document {name}"
     return name
 
+# ----------------------------------------------------------------------
+# Participant-facing source links
+# ----------------------------------------------------------------------
+# Keyed by the exact filename used in the RAG corpus.
+# If a source has a public/participant-accessible URL, add it here.
+# If it does not, leave it out or set it to None; its citation will remain
+# plain text rather than clickable.
+
+SOURCE_REGISTRY = {
+    "Autologous Stem Cell Transplant for Multiple Myeloma (IMF, 2026).pdf":
+        "https://www.myeloma.org/autologous-stem-cell-transplant",
+    "Bispecific Therapies for Multiple Myeloma (International Myeloma Foundation, 2026).pdf":
+        "https://www.myeloma.org/emerging-therapies/bispecific-therapies",
+    "Blood Protein Tests for Multiple Myeloma (IMF, 2025).pdf":
+        "https://www.myeloma.org/blood-protein-testing",
+    "Bone Marrow Tests for Multiple Myeloma (IMF, 2025).pdf":
+        "https://www.myeloma.org/bone-marrow-tests",
+    "CAR T-Cell Therapy for Multiple Myeloma (International Myeloma Foundation, 2024).pdf":
+        "https://www.myeloma.org/emerging-therapies/car-t-cell-therapy",
+    "Comprehensive Molecular Profiling of Multiple Myeloma by African and European Ancestry (Manojlovic et al., 2017).pdf":
+        "https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1007087",
+    "Durie-Salmon Staging for Multiple Myeloma (IMF, 2026).pdf":
+        "https://www.myeloma.org/durie-salmon-staging",
+    "FDA Approval of Teclistamab Plus Daratumumab for Relapsed Multiple Myeloma (2026).pdf":
+        "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-combination-daratumumab-hyaluronidase-fihj-relapsed-or-refractory-multiple",
+    "First-Line Treatment for Multiple Myeloma (IMF, 2026).pdf":
+        "https://www.myeloma.org/frontline-treatment-options",
+    "Genetic Heterogeneity and Drug Resistance in Relapsed Multiple Myeloma (Vo et al., 2022).pdf":
+        "https://www.nature.com/articles/s41467-022-31430-0",
+    "Genetic Heterogeneity in Multiple Myeloma and Targeted Therapy (Lohr et al., 2014).pdf":
+        "https://www.cell.com/cancer-cell/fulltext/S1535-6108(13)00542-4?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1535610813005424%3Fshowall%3Dtrue",
+    "Immunocytokine Therapy for Multiple Myeloma (International Myeloma Foundation, 2026).pdf":
+        "https://www.myeloma.org/emerging-therapies/immunocytokine-therapy",
+    "Initial Genome Sequencing of Multiple Myeloma (Chapman et al., 2011).pdf":
+        "https://www.nature.com/articles/nature09837",
+    "ISS and R-ISS Staging for Multiple Myeloma (IMF, 2026).pdf":
+        "https://www.myeloma.org/international-staging-system-iss-reivised-iss-r-iss",
+    "Kidney Function Tests for Multiple Myeloma (IMF, 2025).pdf":
+        "https://www.myeloma.org/myeloma-kidney-tests",
+    "M-Protein Tests for Multiple Myeloma (IMF, 2026).pdf":
+        "https://www.myeloma.org/monoclonal-protein-tests",
+    "Maintenance Therapy for Multiple Myeloma (IMF, 2024).pdf":
+        "https://www.myeloma.org/maintenance-therapy",
+    "Mayo Clinic mSMART Relapsed Myeloma Treatment Guidelines, Version 9 (2026).pdf":
+        "https://static1.squarespace.com/static/5b44f08ac258b493a25098a3/t/69b45653e3e1365b6857a106/1773426259531/03_13_26_v9+Relapsed+MM+mSMART%2BRelapsedMM.pdf",
+    "MGUS, Smoldering Myeloma, and Active Myeloma (IMF, 2026).pdf":
+        "https://www.myeloma.org/what-are-mgus-smm-mm",
+    "Minimal Residual Disease in Multiple Myeloma (IMF).pdf":
+        "https://www.myeloma.org/videos/minimal-residual-disease-mrd",
+    "Multiple Myeloma Autologous Stem Cell Transplantation Patient Toolkit (MMRF, 2026).pdf":
+        "https://themmrf.org/wp-content/uploads/2026/03/Autologous-Stem-Cell-Transplantation-patient_toolkit-2026.pdf",
+    "Multiple Myeloma Blood Tests (IMF, 2026).pdf":
+        "https://www.myeloma.org/multiple-myeloma-blood-tests",
+    "Multiple Myeloma Complications (IMF, 2025).pdf":
+        "https://www.myeloma.org/medical-conditions",
+    "Multiple Myeloma Diagnosis and Treatment (Mayo Clinic, 2024).pdf":
+        "https://www.mayoclinic.org/diseases-conditions/multiple-myeloma/diagnosis-treatment/drc-20353383",
+    "Multiple Myeloma FAQ (IMF, 2026).pdf":
+        "https://www.myeloma.org/myeloma-cancer-questions",
+    "Multiple Myeloma Imaging Studies (IMF, 2025).pdf":
+        "https://www.myeloma.org/multiple-myeloma-imaging-studies",
+    "Multiple Myeloma Immunotherapy Patient Toolkit (MMRF, 2026).pdf":
+        "https://themmrf.org/wp-content/uploads/2026/03/Immunotherapy-patient_toolkit-2026.pdf",
+    "Multiple Myeloma Overview (IMF, 2026).pdf":
+        "https://www.myeloma.org/what-is-multiple-myeloma",
+    "Multiple Myeloma Relapse (IMF, 2025).pdf":
+        "https://www.myeloma.org/treatment/relapse-definition",
+    "Multiple Myeloma Signs and Diagnosis (IMF, 2025).pdf":
+        "https://www.myeloma.org/newly-diagnosed/do-you-have-myeloma",
+    "Multiple Myeloma Staging and Risk Stratification (IMF, 2019).pdf":
+        "https://www.myeloma.org/multiple-myeloma/multiple-myeloma-prognosis-staging",
+    "Multiple Myeloma Testing (IMF, 2026).pdf":
+        "https://www.myeloma.org/multiple-myeloma-tests",
+    "Multiple Myeloma Testing, Staging and Prognosis (IMF, 2025).pdf":
+        "https://www.myeloma.org/tests-staging",
+    "NCCN Multiple Myeloma Patient Guidelines (2026).pdf":
+        "https://www.nccn.org/patients/guidelines/content/PDF/myeloma-patient.pdf",
+    "Perspectives on the Risk-Stratified Treatment of Multiple Myeloma (Davies et al., 2022).pdf":
+        "https://pmc.ncbi.nlm.nih.gov/articles/PMC9894570/",
+    "Quality of Life in Longitudinal Multiple Myeloma Studies (Nielsen et al., 2017).pdf":
+        "https://onlinelibrary.wiley.com/doi/10.1111/ejh.12882",
+    "Quality of Life in Multiple Myeloma Treatment (Sonneveld et al., 2013).pdf":
+        "https://www.nature.com/articles/leu2013185",
+    "Questions to Ask Your Myeloma Doctor (IMF).pdf":
+        "https://www.myeloma.org/resource-library/tip-card-ask-your-doctor",
+    "Routine Health Screenings for Myeloma Patients (IMF, 2021).pdf":
+        "https://www.myeloma.org/health-screenings",
+    "The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development (Anderson et al., 2017).pdf":
+        "https://aacrjournals.org/clincancerres/article/23/15/3980/257045/The-Role-of-Minimal-Residual-Disease-Testing-in",
+    "Types of Multiple Myeloma (IMF, 2025).pdf":
+        "https://www.myeloma.org/types-of-myeloma",
+}
 
 # ----------------------------------------------------------------------
 # Embedding (Gemini) with batching + disk cache
@@ -331,6 +423,22 @@ class KnowledgeBase:
         except Exception:
             return False
 
+    def source_link_map(self):
+        """
+        Map the human-readable document titles used in chatbot citations
+        to participant-accessible URLs.
+
+        Sources without a URL remain plain-text citations.
+        """
+        links = {}
+
+        for source in self.sources:
+            url = SOURCE_REGISTRY.get(source)
+            if url:
+                links[source_title(source)] = url
+
+        return links
+    
     # ---- retrieve ----
     def retrieve(self, client, query, k=TOP_K, embed_batch=_embed_batch):
         if not self.ready: